Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Acerus Buys Back All Remaining U.S. Rights for NATESTO From Aytu

Executive Summary

Aytu BioScience Inc. licensed exclusive US marketing rights to Acerus Pharmaceuticals Corp.'s Natesto (testosterone), a nasal gel FDA-approved for testosterone replacement therapy in adult males diagnosed with hypogonadism.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Nasal
      • Topical Delivery
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register